Lupin launches generic conjunctivitis treatment medicine in US
New Delhi: Domestic pharma major Lupin Ltd on Wednesday said it has launched in the US market its generic version of Moxifloxacin Hydrochloride Ophthalmic solution used for treating bacterial conjunctivitis.
The launch follows receipt of approval from the US Food and Drug Administration (USFDA) earlier for Moxifloxacin Hydrochloride Ophthalmic solution 0.5 per cent, the company said in a statement.
The product is produced at Lupin's Pithampur manufacturing facility, it added.
The medicine is generic equivalent of Novartis Pharms Corp's Vigamox Ophthalmic solution.
The launch follows receipt of approval from the US Food and Drug Administration (USFDA) earlier for Moxifloxacin Hydrochloride Ophthalmic solution 0.5 per cent, the company said in a statement.
The product is produced at Lupin's Pithampur manufacturing facility, it added.
The medicine is generic equivalent of Novartis Pharms Corp's Vigamox Ophthalmic solution.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd